Rheumatology

Results show a significantly higher risk of death and combined poor outcomes compared with patients without lupus and both with and without other comorbidities.

How much do you know about the treatment of patients with rheumatoid arthritis? Find out now with our quiz.

The Epionics SPINE is an innovative tool to assess the spinal mobility of patients with axial spondyloarthritis.

Investigators set out to determine the effect on social media use in relation to disease severity and sleep quality in patients with fibromyalgia.

The indication granted Monday makes the 2-dose vaccine the very first approved by the FDA for the prescribed prevention of COVID-19.

Test your knowledge with our Rheumatoid Arthritis: 2021 Highlights quiz!

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 20, 2021.

In this retrospective study, investigators analyzed patients with newly diagnosed RA, to determine if short-term, low doses (< 10 mg/day) of prednisone would help DAS28-ESR score.

Susan Chrostowski, DNP, MS, APRN discusses her presentation, entitled “Demystifying Fibromyalgia for the Nurse and Advanced Practice Provider.”

The stigma surrounding gout has contributed to the general unease patients have about their condition.

Research suggests that men and women of all ages in mainland China recorded similar results of untreated osteoporosis and vertebral and clinical fractures, all of which are becoming more prevalent over time.

Anakinra treatment may reduce mortality risk in patients with moderate-to-severe COVID-19, especially for those with hyperinflammation.

Daniel Hernandez, MD, and Esteban Rivera discuss the study, “Social Listening: Factual vs. Misinformation YouTube Spanish-Language Rheumatoid Arthritis Videos,” presented at the 23rd Pan-American Conference of Rheumatology (PANLAR) 2021.

Bryant England, MD, discusses his presentation entitled, “Epidemiology of Multimorbidity in Rheumatoid Arthritis."

The US Food and Drug Administration (FDA) announced it has authorized a third dose of either the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccines for patients with compromised immune systems, such as patients with rheumatic disease.

Test your knowledge of rheumatoid arthritis with our "Best of 2020" quiz!

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 13, 2021.

Patients with rheumatic disease reported significant employment status changes, which may imply issues with healthcare access, affordable medication, mental health concerns, and rheumatic disease activity. However, they tended to follow public health advice and continued therapy to mitigate the risk of COVID-19 diagnosis.

John Cush, MD, discusses his upcoming lecture entitled, “Rheumatoid Arthritis: Year in Review,” which will be presented at the Congress of Clinical Rheumatology.

Randall Cron, MD, PhD, discuss his lectures entitled, “The Immunology of COVID” and “The Role of Rheumatologists in COVID-19,” which will be presented at the Congress of Clinical Rheumatology.

Brian LaMoreaux, MD, MS, discusses the recent study entitled, "Improving outcomes for patients hospitalised with gout: a systematic review."

Alexis Ogdie-Beatty, MD, discusses the UPLIFT survey and UPLIFT Innovation Challenge, the unmet needs of patients with psoriatic arthritis, and the clinical significance of the survey’s results.

Compared with controls, patients with psoriatic arthritis presented more often with depression at baseline and patients with rheumatoid arthritis had a higher incidence of cardiovascular comorbidity after 3 years.

Leonard Calabrese, DO, discusses his findings entitled, “Applied Immunology to Autoimmune Diseases: COVID-19 as Immunology,” which was presented at the Rheumatology Nurses Society Conference.

Only 11% of patients reported a flare that required treatment and no participants experienced severe flares. Approximately 60% of flares occurred after D2.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending August 6, 2021.

Although it is assumed that fatigue is related to inflammation, disease activity, or treatment with drugs such as Methotrexate, it can affect children independent of disease activity and impacted by psychosocial factors.

The risk of developing systemic lupus erythematosus (SLE) was reduced by 19% with every increase in a healthy lifestyle index score (HLIS). The risk of dsDNA positive SLE reduced 22% with the addition of each healthy behavior. Those with genetic risk factors may be able to reduce their risk of SLE diagnosis by almost 50% with adherence to healthy lifestyle behaviors.

Richard Furie, MD, discusses the recent FDA approval of anifrolumab-fnia for the treatment of patients with systemic lupus.

Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”